ProMIS Neurosciences Granted US Patent 12,071,472 For "Methods Of Reducing Toxicity Induced By Amyloid Beta Oligomers Using Antibodies Specific To A-Beta Oligomers" In Alzheimer's Treatment
ProMIS Neurosciences Granted US Patent 12,071,472 For "Methods Of Reducing Toxicity Induced By Amyloid Beta Oligomers Using Antibodies Specific To A-Beta Oligomers" In Alzheimer's Treatment
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.